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Rationalising medications through deprescribing
Careful judgment is required to optimise benefit and minimise harm
Anthony J Avery professor of primary healthcare, Brian G Bell research fellow
Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, UK
With an ageing population and growth in multimorbidity and
polypharmacy, increasing attention is being paid to
deprescribing. This term has become widely used in recent
years, and there are numerous definitions.1 Put simply, it is the
process of withdrawing drugs to try to improve outcomes.2 But
it is important to recognise this is a complex process; careful
judgment is required to balance the potential risks and benefits
of withdrawing medicines.
Since TheBMJ last published an editorial on deprescribing in
20142 at least three systematic reviews have been published3-5
as well as several studies not included in these reviews.6-8 Here
we consider the latest evidence and guidance on withdrawing
drug treatments.
Clearly, patients should receive only the medications that they
want and need. If deprescribing is required it’s important to
know the safest and most effective approach, what resources
are needed to do it properly, and the likely ratio of costs to
benefits for patients and health services.
Multiple studies of polypharmacy or deprescribing have shown
that interventions by pharmacists, doctors, or multidisciplinary
teams can reduce the number of medications that patients take3
and reduce the prevalence of potentially inappropriate
prescribing.5 These reductions tend to be modest, however. For
example, in one meta-analysis patients were taking an average
of 7.4 drugs at baseline; during follow-up this fell by 0.2 drugs
in intervention groups and increased by 0.2 drugs in control
groups.
Modest effects
Research on clinical outcomes is also growing. Overall,
deprescribing seems to be safe, but the evidence on benefits
remains mixed.3-5 A meta-analysis of randomised trials showed
no overall reduction in mortality from deprescribing
interventions,4 although a subgroup analysis confined to
interventions targeted at patients (rather than education for
clinicians) did suggest a mortality benefit (odds ratio 0.62, 95%
confidence intervals 0.43 to 0.88, relative to controls). In another
meta-analysis, strategies to reduce polypharmacy did not reduce
mortality3 or hospital admissions. At least 15 studies have
examined the effects of deprescribing on quality of life, and
only one of these reported a benefit (which was modest).4
Reliable cost effectiveness data are scarce. Although reducing
prescribing, particularly hazardous prescribing, might be
expected to save money, these savings must be offset against
the cost of the deprescribing intervention. One recent analysis9
suggests that interventions to reduce polypharmacy are cost
saving overall, but more research is needed to identify the most
cost effective strategies and their key elements.10
The available guidance and published evaluations highlight that,
done properly, deprescribing is complex and time consuming.
When patients are taking multiple drugs, each must be carefully
considered in the context of likely benefits and harms,
therapeutic indications, potential drug interactions, the
preferences of patients and carers, and adherence. A Scottish
study estimated that this takes up to 30 minutes for a doctor and
75 minutes for a pharmacist.9 Health services should be under
no illusion that benefits can be achieved in the single short
consultations typical of general practice appointments in the
UK. Investment is required to fund pharmacists, doctors, or
multidisciplinary teams to do this work.
Considerable advice is available on deprescribing. Guidance
from the Scottish Government Polypharmacy Model of Care
Group is particularly helpful, offering a seven step process for
reviewing medications.10 Key aspects include a strong focus on
what matters to each patient and an emphasis on empowering
and supporting patients in their decision making around
medicines. Although there is some uncertainty whether shared
decision making improves outcomes,11 a European consortium
has made a strong case for informed discussions and shared
decisions in deprescribing interventions for patients taking
multiple drugs.12 There is a strong ethical argument too:
respecting autonomy demands detailed discussion of the
expected benefits and risks of all medicines, recognising that
these can change over time, particularly with age or increasing
frailty.
More research is needed to help identify the best approaches to
deprescribing, and it’s important to do this in collaboration with
patients. Nevertheless, based on reasonably substantive evidence
so far, it is unlikely that we are going to see major breakthroughs
in this area. Probably the best we can expect is modest
reductions in medication load and hazardous prescribing, and
modest improvements in patient outcomes. Given the complexity
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of the task, overall cost savings are also likely to be modest.
Deprescribing remains a worthwhile investment, however, and
should be done in partnership with the patients and families
who cope every day with burdensome polypharmacy.
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